1. health and fitness
2. disease
3. diabetes

75th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GLANCE
FRIDAY, JUNE 5, 2015:
8:00 a.m. – 1:45 p.m.
Turning Words into Action in Type 2 Diabetes
Sponsored by Institute for Medical and Nursing Education, Inc. And International Medical Press
Supported by an educational grant from AstraZeneca
Contact: Edwin Odoemelam
Phone: +44-207-398-0608
Email: Edwin.odoemelam@intmedpress.com
Location: Westin Boston Waterfront, Harbor Ballroom
This highly interactive workshop is organized by the Global Partnership for Effective Diabetes
Management and is designed for healthcare professionals from around the globe, focusing on the need
for early glycemic control to reduce diabetes-related complications, and discussion on how to overcome
barriers to achieving goals safely.
6:30 p.m. – 9:30 p.m.
6:30 p.m. – 7:00 p.m. – Registration and Dinner
7:00 p.m. – 9:30 p.m. – Educational Program
El Panorama Cambiante Sobre el Tratamiento de la Diabetes Tipo 2 con Insulina (Presentado en
Español)
Jointly sponsored by University of Texas Southwestern Medical Center and Worldwide Initiative for
Diabetes Education
Supported by an unrestricted educational grant from Novo Nordisk
Contacts:
Mark Vinciguerra, University of Texas Southwestern Medical Center
Phone/Email: 214-648-4852; Mark.Vinciguerra@UTSouthwestern.edu
Jane Savio, Worldwide Initiative for Diabetes Education
Phone/Email: 212-614-4337; Jane.Savio@worldwidediabetes.org
Location: Westin Boston Waterfront, Harbor Ballroom
Este simposio se enfocará en insulinas y nuevas tendencias en terapias de insulina, como es que están
redefiniendo el cuidado de la diabetes tipo 2 hoy en día y que esperanza están aportando para hacer
frente a la creciente demanda mundial debido al crecimiento de la diabetes y sus complicaciones.
6:30 p.m. – 9:30 p.m.
6:30 p.m. – 7:00 p.m. – Program Registration and Buffet Dinner
7:00 p.m. – 9:00 p.m. – CME Scientific Program
Novel Mechanisms and Advancing Therapeutic Paradigms for Optimizing LDL-Focused Management
and Cardioprotection in the Diabetic Patient
Sponsored by CMEducation Resources
Updated 5/14/15 (for website)
Supported by an educational grant from Sanofi US-Regeneron
Contact: Milo Falcon
Phone: 888-977-1625
Location: Boston Marriott Copley Place, Grand Ballroom G-K
This symposium will discuss novel mechanisms and advancing therapeutic paradigms for optimizing LDLfocused management and cardioprotection in diabetic patients. It will focus on clinical trials,
mechanisms of atherosclerotic heart disease, novel LDL targets and therapies, and new translational
dimensions of applying advances in LDL reduction to the diabetes population.
6:30 p.m. - 9:30 p.m.
6:30 p.m. – 7:00 p.m. - Dinner
7:00 p.m. – 9:30 p.m. – Program
Comprehensive Management of DM - Focus on SGLT2 Inhibitors and Combination Therapy - Emerging
Concepts of Renal Effects
Provided by Metabolic Endocrine Education Foundation, PESI Inc., and Medtelligence
Supported by an educational grant from AstraZeneca
Contact: Chris Archibald
Phone: 732-977-5887
Email: carchibald@medtelligence.net
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
The overall objective of this CME program is to describe the management of diabetes, discussing early
combination therapy and how to achieve goals safely without hypoglycemia or weight gain. The varied
effects of newer agents, including SGLT2 inhibitors and incretin-based therapy (DPP4 inhibitors and
GLP1 receptor agonists), and their potential combinations will be evaluated. The efficacy of such
approaches in glycemic control, the effects on weight and blood pressure, and emerging information
about potential positive effects on renal function will be addressed, providing expert insight on the
implications of these findings for the long-term management of diabetes.
Faculty: Zachary T. Bloomgarden, MD, Chair, Yehuda Handelsman, MD, Chair, Stefano Del Prato, MD,
Lawrence A. Leiter, MD, Matthew R. Weir, MD
You may view the Agenda and program information at: http://metabolicfoundation.com/ada2015
SATURDAY, JUNE 6, 2015:
5:30 a.m.- 7:30 a.m.
5:30 a.m. – 6:00 a.m. – Breakfast
6:00 a.m. – 7:30 a.m. – Symposium
Clinical Issues in Type 2 Diabetes: Discussions and Debates Around GLP-1 Receptor Agonists
Jointly provided by Clinical and Patient Educators Association and Integritas Communications
Supported by an educational grant from AstraZeneca
Contact: Barbara Jean Wynne
Phone: 201-535-4941
Updated 5/14/15 (for website)
Location: Boston Marriott Copley Place, Grand Ballroom G-K
During this Clinical Issues™ program, experts in diabetes research and patient care will discuss and
debate a set of topics related to the potential clinical roles of GLP-1 receptor agonists. Throughout the
program, the faculty panel will provide practical consensus recommendations for areas in which
published evidence for GLP-1 receptor agonists has only recently emerged.
5:30 a.m.- 7:45 a.m.
Insulin-Based Options: Current Treatment Strategies and the Potential Impact of Emerging Options on
Patient Outcomes
5:30 a.m. – 5:45 a.m. – Breakfast & Arrivals
5:45 a.m. – 7:45 a.m. – Symposium
Sponsored by Global Directions in Medicine, Inc.
Supported by an educational grant from Novo Nordisk, Inc.
Contact: Deanna Schuly
Email: dschuly@gdmedicine.com
Location: Boston Marriott Copley Place, Grand Ballroom A-F
This symposium is designed to improve clinicians’ awareness of the significance of timely glycemic
management and initiating and intensifying insulin treatment when appropriate. The latest evidencebased information on emerging insulin therapy, which may help to achieve glycemic goals with lower
risks of hypoglycemia and weight gain, will be reviewed.
5:30 a.m.- 7:45 a.m.
Managing the High Risk Patient – LDL and Beyond: Contemporary and Future Approaches
Provided by Metabolic Endocrine Education Foundation, PESI Inc., and Medtelligence
Supported by educational grants from Amgen, Inc. and Amarin Pharma Inc.
Contact: Chris Archibald
Phone: 732-977-5887
Email: carchibald@medtelligence.net
Location: Westin Boston Waterfront, Harbor Ballroom
Despite the availability of numerous clinical guidelines for the management of lipids to reduce
cardiovascular disease (CVD), appropriate application of these guidelines remains low, likely contributing
to CVD morbidity and mortality. The overall objectives of this CME program are to examine the
prevalence of CVD in the high-risk patient, discuss and contrast guidelines, provide an update on
pharmacological strategies to reduce CVD risk, and discuss expert insights into how to apply the lipid
management guidelines and applicable treatment target goals to achieve better patient outcomes.
Faculty: Yehuda Handelsman, MD, Chair, Lawrence A. Leiter, MD, Jorge Plutzky, MD, James A.
Underberg, MD, MS, and Howard S. Weintraub, MD
6:15 p.m. - 8:45 p.m.
6:15 p.m. – 7:00 p.m. – Registration and Dinner
7:00 p.m. – 8:45 p.m. – Symposium
Updated 5/14/15 (for website)
Seeing into the Future: Preventing, Diagnosing and Treating Diabetic Eye Disease
Sponsored by FocusCME
Supported by educational grants from Regeneron Pharmaceuticals and Allergan, Inc.
Contact: Steven Scrivner
Email: meded@focuscme.com
Location: Boston Marriott Copley Place, Grand Ballroom G-K
The goal of this activity is to reinforce traditional strategies and educate clinicians about new strategies
for managing the eye health of patients with diabetes. An emphasis will be placed on the need for
enhanced communication with the eye care specialist, as well as a general understanding of the
therapeutic options available to aid in patient counseling.
Faculty: John E. Anderson, MD; Ralph A. DeFronzo, MD; John W. Kitchens, MD
6:15 p.m. - 9:00 p.m.
6:15 p.m. – 7:00 p.m. – Registration and Dinner
7:00 p.m. – 9:00 p.m. – Scientific Program
Patient-Centered Management of Type 2 Diabetes: A Focus on the Newer Antihyperglycemic Agents
Sponsored by Institute for Medical and Nursing Education, Inc.
Supported by an educational grant from AstraZeneca
Contact: Katie Fidanza
Phone: 404-443-1511
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
Current type 2 diabetes mellitus (T2DM) treatment guidelines emphasize individualized glycemic targets
and patient-centered treatment regimens. This highly interactive symposium will use standardized
patients to demonstrate effective techniques for providing patient-centered T2DM care using newer
classes of antihyperglycemic agents, including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1
receptor agonists, and sodium-glucose cotransporter 2 inhibitors. Practical, evidence-based
recommendations for individualizing therapy in T2DM patients with common comorbidities—
cardiovascular disease, chronic kidney disease, or obesity will be featured.
6:15 p.m. - 9:15 p.m.
Eighth Annual Gerald J. Friedman Fellows Symposium "Nutrition, Diabetes and Human Health"
Sponsored by Tufts University, Friedman School of Nutrition Science and Policy
Supported by an educational grant from Gerald J. and Dorothy R. Friedman New York Foundation for
Medical Research
Contact: Leonid Poretsky, MD
Phone: 212-434-3662
Location: Westin Boston Waterfront, Harbor Ballroom
Since 2000 the Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research has
supported the work of 41 research fellows (for details see http://friedmanfellows.com/fellows/). The
Updated 5/14/15 (for website)
8th Annual Friedman Fellows Symposium will have the following program: Oral and poster presentation;
A debate titled, “Obesity, Nature and Nurture” with plenary speakers Drs. Jeffrey Flier and Terry
Maratos-Flier of Harvard Medical School. Friedman Fellows will address a variety of issues related to
nutrition, diabetes and human health.
6:15 p.m. - 9:15 p.m.
Type 2 DM- Emerging Therapeutic Trends in OADs and Insulin Combinations
Sponsored by Scripps Health
Supported by an educational grant from Sanofi Aventis
Contact: Athena Philis-Tsimikas, MD
Phone: 858-678-7077
Location: Boston Marriott Copley Place, Grand Ballroom A-F
This symposium will highlight the latest concepts in the treatment of diabetes and will focus on:
• Unmet needs and treatment patterns of patients with type 2 diabetes on basal insulin
• Knowledge of new basal insulins in development
• Strategies to mitigate identified barriers to basal insulin-mediated glucose control
Symposium to cover:
• Latest recommendations for advancing diabetes care
o Review 2015 Standards of Care
o How do new therapeutic classes fit into the treatment regimen
o Interactive case discussions with audience response technology
• Emerging basal insulins in development
o Review current unmet needs
o Overview of agents in development
o Recent clinical trial results
• Strategies for advancing basal insulin therapy and addressing patient barriers
o Combination therapies to optimize control
o Interactive case discussions with audience response technology
SUNDAY, JUNE 7, 2015:
5:00 a.m.- 7:45 a.m.
5:00 a.m. – 5:30 a.m. – Registration and Breakfast
5:30 a.m. – 7:45 a.m. – CME Symposium
Complementary Treatments to Enhance Insulin Efficacy: Theory and Strategies
Sponsored by Joslin Diabetes Center
Supported by an educational grant from sanofi-aventis US
Contact: Sherlyn B. Celone
Phone: 203-451-3164
Location: Westin Boston Waterfront, Harbor Ballroom
Updated 5/14/15 (for website)
Today’s selection of antidiabetes medications improves efficacy and individualization. Yet our nonspecialist colleagues often find the options, combinations and barriers to therapeutic advancement
daunting. This program will address combined GLP-1 RA/basal insulin, and help empower specialists to
be more effective resources for primary care in achieving optimal glycemic control.
6:45 p.m. - 9:00 p.m.
6:45 p.m. – 7:30 p.m. – Dinner
7:30 p.m. – 9:00 p.m. – Symposium
Addressing Postprandial Glucose Excursions in T2DM with Inhaled Insulin
Sponsored by MediKinetics
Supported by an educational grant from Sanofi
Contact: Katie McGowan
Phone: 858-717-2940
Location: Westin Boston Waterfront, Harbor Ballroom
A recently approved inhaled insulin provides a convenient prandial option that does not require multiple
daily injections and more closely mimics prandial insulin secretions in healthy adults. The drug-device
combination is a dry formulation of human insulin delivered through a small inhaler that is administered
at the start of a meal. Join our symposium to learn more!
6:45 p.m. - 9:15 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:15 p.m. – CME-certified Activity
Avoiding “Loss of Chance”….Improving the Screening, Treatment and Referral of Patients with
Diabetic Retinopathy
Provided by Vindico Medical Education
Supported by an educational grant from Genentech, Inc.
Contact: Emily Scully
Phone: 856-994-9400
Email: escully@vindicocme.com
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in
the United States, in part because many patients are not identified as needing therapy. In addition to
counseling patients on the impact glucose control have on maintaining vision, clinicians should
emphasize the need for vision screening among patients with diabetes. Early detection offers the best
long-term visual outcomes, and is even more important with a new treatment approved for the
management of diabetic retinopathy and another being considered. In this activity, leading
endocrinologists and retina specialists will discuss preventive measures that clinicians can take to delay
or prevent vision loss in patients with diabetes and review the latest data on treatment options for
patients with diabetic eye disease.
7:00 p.m. - 9:30 p.m.
Updated 5/14/15 (for website)
7:00 p.m. – 7:30 p.m. – Registration and Buffet Dinner
7:30 p.m. – 9:30 p.m. – Activity
The Evolution of Insulin: Applying the Fundamentals of Insulin Physiology to Build a Better Insulin
Sponsored by Creative Educational Concepts, Inc.
Supported by an educational grant from Lilly
Contact: Ashley C. Lilly
Phone: 859-260-1717 x117
Location: Boston Marriott Copley Place, Grand Ballroom G-K
The goal of this activity is to explore key differences between exogenous insulin administration and
normal endogenous insulin physiology to better understand the limitations of current insulin
preparations and the need to “build a better insulin.” Expert faculty will examine the metabolic
abnormalities and adverse effects associated with exogenous insulin administration resulting from overinsulinization of the peripheral tissues and loss of the normal hepatic to peripheral insulin gradient.
Attendees will gain an appreciation of the “evolution” of insulin preparations from discovery to their
future in modern medicine.
MONDAY, JUNE 8, 2015:
5:30 a.m. - 7:45 a.m.
5:30 AM – 6:15 AM – Breakfast
6:15 AM – 7:45 AM – Presentation
Reducing Residual CVD Risk: Shifting the Cholesterol Conversation Beyond Statin Therapy
Sponsored by Creative Educational Concepts, Inc.
Supported by an educational grant from Lilly
Contact: Rebecca Weaver
Phone: 859-260-1717
Location: Boston Marriott Copley Place, Grand Ballroom G-K
The goal of this interactive activity is to explore the controversies surrounding the new ACC/AHA
cholesterol guidelines; examine the evidence and rationale for using non-statin therapies to reach target
lipid goals; determine the role and practical impact of CETP inhibition in lipid disorders; and discuss
recent clinical trial data with CETP inhibitors currently in development. Attendees will gain an
appreciation of the need to “shift the cholesterol conversation” beyond statin therapy in order to
reduce residual cardiovascular risk for appropriate patients.
6:45 p.m. – 9:15 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:15 p.m. – CME-certified Activity
Combining Therapeutic Advances with Patient Engagement to Optimize Treatment for Patients with
Obesity
Provided by Vindico Medical Education
Supported by an educational grant from Novo Nordisk
Updated 5/14/15 (for website)
Contact: Emily Scully
Phone: 856-994-9400
Email: escully@vindicocme.com
Location: Westin Boston Waterfront, Harbor Ballroom
Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. In
addition, various medical societies have issued recommendations to guide the use of available
treatments for obesity. Obesity is a particularly challenging condition in terms of motivating patients to
adhere to behavioral and pharmacologic regimens that in many cases require a lifetime commitment. In
the last few years, there has been considerable development in pharmacologic options for managing
obesity, requiring clinicians to have a thorough understanding of the efficacy and risks associated with
each agent in order to help patients determine the most appropriate medication. In this highly
interactive program, leading specialists will summarize the latest guidelines for the management of
obesity, discuss how to encourage adherence among patients and review all pharmacologic options for
the management of obesity in case presentations that allow learners to manage patients along with the
panel.
6:45 p.m. - 9:30 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:30 p.m. – Symposium
CV Outcomes with T2D Agents: Application of New Data and Key Takeaways for Your Type 2 Diabetes
Practice
Sponsored by Medscape Education
Supported by an educational grant from Merck
Contact: Kelly Hanley
Phone: 973-670-1861
Location: Renaissance Boston Waterfront Hotel, Pacific Grand Ballroom
This live event will address the following learning objectives:
• Identify the rationale for cardiovascular (CV) outcomes trials in patients with type 2 diabetes
• Review clinical data related to antihyperglycemic agents and CV outcomes
• Assess clinical and practical implications of CV outcomes with antihyperglycemic agents trials
6:45 p.m. - 9:30 p.m.
6:45 p.m. – 7:15 p.m. – Registration and Dinner
7:15 p.m. – 9:30 p.m. – CME-certified Activity
A Patient-Centered Approach: Treatment Intensification and HbA1c Management
Sponsored by Dannemiller and Spire Learning
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
Contact: Elysa Ripa
Phone: 973-753-2438
Location: Boston Marriott Copley Place, Grand Ballroom G-K
Updated 5/14/15 (for website)
This symposium will feature the latest evidence on T2DM treatments recently approved by the
FDA. You’ll be provided the most up-to-date information on intensification of anti-hyperglycemic
regimens and coordination of care – key learnings to help better address treatment intensification in
your diabetes patients.
This highly interactive program will use real-world case presentations and small-group learning that will
focus on a team-based approach and key challenges in T2DM management. Clinical case examples will
focus on incorporating new therapies into diabetes management, and improving patient education and
coordination of care. The program will also include a case-based workshop.
You’ll leave with the latest on new therapies and treatment intensification, treatment efficacy and
safety data, tactics for enhanced patient education to reach HbA1c goals, and coordination of care for
patients with T2DM to share with your team.
Updated 5/14/15 (for website)